Longevity company HexemBio Unveils Three Generation Product Line, Backed by $15.5 Million in Total Funding
New investors join Draper Associates and Boost VC as the company moves its lead cell therapy toward human trials and develops its second-generation injectable SAN FRANCISCO, CA, UNITED STATES, September 15, 2026 /EINPresswire.com/ -- HexemBio, the …